A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors

Completed · Phase 1

Conditions studied: Advanced or Metastatic Solid Tumors

In brief

Primary Objectives: * To determine the safety, toxicity and the maximum tolerated dose (MTD) of intravenous STA-5312 when administered weekly (3 of 4 weeks) to subjects with advanced or metastatic solid tumors. * To determine the pharmacokinetics of STA-5312. Secondary Objective: • To assess antitumor activity of STA-5312 administration.

Key facts

Study ID

NCT00276913

Run by

Synta Pharmaceuticals Corp.

People needed

30

Starts

2004-06-01

Last updated by the study team

2014-02-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female subjects aged at least 18 years with histologically-confirmed non hematological malignancy that is metastatic or unresectable and for which no standard therapy exists.
• Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2.
• Peripheral neuropathy less than Grade 2 on National Cancer Institute Common Toxicity Criteria (NCI CTC) version 3 adverse event scale.
• Subjects must have acceptable organ and marrow function during the Screening Period as defined below. (Note: Subjects must meet these criteria at each pre-dose visit to receive additional doses of STA-5312).
• Absolute neutrophil count (ANC) greater than 1500 cells/µL
• Platelets greater than 100,000/µL
• Total bilirubin must be <1.5 times ULN
• Aspartate transaminase (AST) ≤3 times ULN or less than 5 times the ULN in subjects with liver metastases
• Alanine transaminase (ALT) ≤3 times ULN or less than 5 times the ULN in subjects with liver metastases
• Adequate renal function (serum creatinine <2.0 mg/dL).
• Electrocardiogram (ECG) without evidence of clinically significant ventricular arrhythmias or active ischemia as determined by the investigator.
• Documented cardiac ejection fraction greater than 50% obtained within 30 days of administration of the first dose.
• The effects of STA-5312 on the developing human fetus are unknown. Therefore, women of childbearing potential (defined as women over 50 years of age or history of amenorrhea for <12 months prior to study entry) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a female subject become pregnant or suspect she is pregnant while participating in this study, she should inform the treating physician immediately.
• Ability to understand and willingness to sign a written informed consent document.

You may not qualify if…

• Women who are pregnant or breast-feeding.
• Subjects who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
• Subjects with previous high-dose chemotherapy with autologous allogeneic hematopoietic stem cell transplantation.
• Subjects with primary brain tumors or active brain metastases are excluded. Subjects with previously treated brain metastases who are not receiving corticosteroids or anticonvulsants are eligible.
• History of stroke within 6 months of treatment or other significant neurological limitations.
• Use of any investigational agents within 4 weeks of study enrollment.
• History of severe allergic reactions to excipients (e.g. Tween 80/polysorbate 80), including severe hypersensitivity reactions defined as greater than Grade 3 based on NCI CTC version 3.
• Uncontrolled intercurrent illness including, but not limited to, human immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral therapy, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Where it is running

• Steven Limentani, MD — Charlotte, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.